Anebulo Pharmaceuticals (FRA:214) Interest Expense : €-0.08 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Anebulo Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Anebulo Pharmaceuticals's interest expense for the three months ended in Mar. 2024 was € -0.06 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.08 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Anebulo Pharmaceuticals's Operating Income for the three months ended in Mar. 2024 was € -1.53 Mil. Anebulo Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was € -0.06 Mil. Anebulo Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Anebulo Pharmaceuticals Interest Expense Historical Data

The historical data trend for Anebulo Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anebulo Pharmaceuticals Interest Expense Chart

Anebulo Pharmaceuticals Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Interest Expense

-0.01

Anebulo Pharmaceuticals Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial										-	-	-	-0.03	-0.06

Anebulo Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.08 Mil.

Anebulo Pharmaceuticals (FRA:214) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Anebulo Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was €-0.06 Mil. Its Operating Income for the three months ended in Mar. 2024 was €-1.53 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was €0.00 Mil.

Anebulo Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Anebulo Pharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Anebulo Pharmaceuticals (FRA:214) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anebulo Pharmaceuticals Inc (FRA:214) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

ANEB:USA

Address

1017 Ranch Road 620 South, Suite 107, Lakeway, TX, USA, 78734

Website

https://www.anebulo.com

Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.

Anebulo Pharmaceuticals (FRA:214) Headlines

No Headlines